JNJ
Johnson JohnsonCNYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-17
Current thesis
Q2 sales growth, higher adjusted EPS, raised full-year guidance, and continued oncology, immunology, neuroscience, and MedTech momentum support a constructive defensive-growth case. [#SEC-8K-2026-07-15]
Posture
Mixed
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.1.
What can break
GAAP earnings and cash flow remain exposed to litigation, acquisition-related, and other special items.
Momentum
45
Value
61
Sentiment
51
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $271.43 · Bull $290.00 · Bear $225.00
Data freshness
Prices
As of 2026-07-17
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-17 • Model: HYBRID_IC_RP
AI Memo
As of 2026-07-16 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-17
Investment thesis
As of 2026-07-17
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Neutral
Target $275.14
Why
Momentum45 · Δ7d -41.5
Value61 · Δ7d -0.1
Sentiment51 · Δ7d +9.4
So what
Balanced signals (Net Neutral). Wait for confirmation before sizing up.
Lead driver: Value · See fundamentals
Momentum
45
26% active weight
Current posture
7d trendSoftening
Δ7d
-41.5
Δ21d
-13.7
Value
61
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
-0.0
Sentiment
51
34% active weight
Current posture
7d trendImproving
Δ7d
+9.4
Δ21d
+8.0
Why this grade
Composite grade C. Momentum 44.5 / Value 61.0 / Sentiment 50.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$609.12B
Beta
0.34
Shares Out
2.41B
P/E (TTM)
19.7
P/S (TTM)
5.34
P/FCF (TTM)
66.85
Rev YoY
+9.9%
EPS YoY
-52.8%
Gross Margin
+68.0%
Op Margin
+34.2%
Net Debt
$29.23B
Current Ratio
1.03
As of 2026-07-17 • Updated nightlySource: Internal modelMethodology